The Developmental Therapeutics Program has achieved national recognition as a major center for the development of novel chemotherapy approaches to pediatric cancer treatment.
Texas Children’s Cancer Center has developed a comprehensive program of drug development and clinical and laboratory-based pharmacology that focuses on the preclinical study and clinical development of new agents to treat pediatric malignancies.
Over 250 active clinical trials
We are currently conducting over 250 clinical trials – more than the majority pediatric cancer centers in the nation.
The most advanced and innovative therapies
Our Developmental Therapeutics Program has been a leader in the study of novel agents for the treatment of cancer and hematologic disorders. Our vast expertise in the development of new therapeutics means our patients have access to the most advanced and innovative therapies.
Our physicians employ evidence-based guidelines and the most advanced clinical trials in the delivery of hematology and oncology care. For example, recognizing that clinical trials are the standard of care for all children with cancer, every eligible patient is considered for entry on National Cancer Institute-approved clinical trials; approximately 80 percent of our patients are registered in these studies. These treatment studies represent leading-edge therapies in the field to provide the best treatments for children with cancer.